# Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen

> **NCT07055295** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 390 (estimated)

## Conditions studied

- Rabies

## Interventions

- **BIOLOGICAL:** Rabies Vaccine (Serum-free Vero Cell), Freeze-dried
- **BIOLOGICAL:** Verorab®

## Key facts

- **NCT ID:** NCT07055295
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07055295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07055295, "Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07055295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*